Vivo Capital’s Cidara Therapeutics CDTX Stock Holding History

Vivo Capital’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-956,670	Closed	-$211M	–	49
2025 Q4	$211M	Sell	956,670 -354,755	-27%	-$57.3M	13.66%	2
2025 Q3	$126M	Hold	1,311,425	–	–	10.11%	3
2025 Q2	$63.9M	Buy	1,311,425 +627,149	+92%	+$15.1M	6.54%	3
2025 Q1	$14.7M	Buy	684,276 +13,676	+2%	+$304K	1.95%	7
2024 Q4	$18M	Buy	+670,600	New	+$10.9M	2.02%	10

Vivo Capital's CDTX Position: Q1 2026 in Review

Vivo Capital sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 956,670 shares — an estimated $211M sold.

Vivo Capital first reported a position in CDTX in Q4 2024 and held it in 5 quarters. The position peaked at $211M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Vivo Capital reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Vivo Capital sold 956,670 Cidara Therapeutics shares in Q1 2026, an estimated $211M.
Vivo Capital first reported a position in Cidara Therapeutics in Q4 2024 and held it in 5 quarters.
Vivo Capital's Cidara Therapeutics position peaked at $211M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.